 The purpose of the study is to evaluate the amount of GLPG1837 and metabolite present in the blood relative bioavailability after a single oral administration of 500 mg GLPG1837 given as an oral suspension under fasted conditions as well as a tablet formulation under fasted and fed conditions, in male healthy subjects. 